CN1177302A - 作为抗肿瘤剂的淋巴毒素-α/β复合体和抗淋巴毒素-β受体抗体 - Google Patents
作为抗肿瘤剂的淋巴毒素-α/β复合体和抗淋巴毒素-β受体抗体 Download PDFInfo
- Publication number
- CN1177302A CN1177302A CN96192271A CN96192271A CN1177302A CN 1177302 A CN1177302 A CN 1177302A CN 96192271 A CN96192271 A CN 96192271A CN 96192271 A CN96192271 A CN 96192271A CN 1177302 A CN1177302 A CN 1177302A
- Authority
- CN
- China
- Prior art keywords
- beta
- activator
- antibodies
- pharmaceutical composition
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (70)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37896895A | 1995-01-26 | 1995-01-26 | |
US08/378,968 | 1995-01-26 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004100070585A Division CN1589902A (zh) | 1995-01-26 | 1996-01-26 | 抗-LT-β-R抗体在制备药用组合物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1177302A true CN1177302A (zh) | 1998-03-25 |
CN1146442C CN1146442C (zh) | 2004-04-21 |
Family
ID=23495285
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004100070585A Pending CN1589902A (zh) | 1995-01-26 | 1996-01-26 | 抗-LT-β-R抗体在制备药用组合物中的应用 |
CNB961922710A Expired - Fee Related CN1146442C (zh) | 1995-01-26 | 1996-01-26 | 作为抗肿瘤剂的淋巴毒素-α/β复合体和抗淋巴毒素-β受体抗体 |
CNA2006101007130A Pending CN1900116A (zh) | 1995-01-26 | 1996-01-26 | 抗-LT-β-R抗体、含有该抗体的药用组合物及其制药应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004100070585A Pending CN1589902A (zh) | 1995-01-26 | 1996-01-26 | 抗-LT-β-R抗体在制备药用组合物中的应用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006101007130A Pending CN1900116A (zh) | 1995-01-26 | 1996-01-26 | 抗-LT-β-R抗体、含有该抗体的药用组合物及其制药应用 |
Country Status (25)
Country | Link |
---|---|
EP (2) | EP1407781A1 (zh) |
JP (2) | JPH10513161A (zh) |
KR (2) | KR100470739B1 (zh) |
CN (3) | CN1589902A (zh) |
AT (1) | ATE268604T1 (zh) |
AU (1) | AU725351B2 (zh) |
BG (1) | BG62599B1 (zh) |
BR (1) | BR9606808A (zh) |
CA (1) | CA2211443A1 (zh) |
CZ (1) | CZ298711B6 (zh) |
DE (1) | DE69632681T2 (zh) |
DK (1) | DK0809510T3 (zh) |
EA (1) | EA000096B1 (zh) |
EE (1) | EE04453B1 (zh) |
ES (1) | ES2220972T3 (zh) |
FI (1) | FI119359B (zh) |
HK (1) | HK1006356A1 (zh) |
HU (1) | HUP9801746A3 (zh) |
NO (1) | NO322744B1 (zh) |
NZ (1) | NZ303405A (zh) |
PL (1) | PL185364B1 (zh) |
PT (1) | PT809510E (zh) |
RO (1) | RO118634B1 (zh) |
SK (1) | SK286497B6 (zh) |
WO (1) | WO1996022788A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101073665B (zh) * | 2006-05-17 | 2014-11-26 | 上海复旦张江生物医药股份有限公司 | 淋巴毒素在制备增加化疗药物敏感性的药物中的应用 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925351A (en) | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
US7118742B2 (en) * | 1997-07-07 | 2006-10-10 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
US6140467A (en) * | 1997-07-07 | 2000-10-31 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
US7060667B1 (en) | 1998-01-30 | 2006-06-13 | Biogen Idec Ma, Inc. | Treatment of follicular lymphomas using inhibitors of the LT pathway |
DE69931944T2 (de) | 1998-10-09 | 2007-02-08 | Biogen Idec Ma Inc., Cambridge | Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges |
EP1326897A2 (en) * | 2000-10-13 | 2003-07-16 | Biogen, Inc. | Humanized anti-lt-beta-r antibodies |
AU2003248782A1 (en) * | 2002-07-01 | 2004-01-19 | Biogen Idec Ma Inc. | Humanized anti-lymphotoxin beta receptor antibodies |
PL377611A1 (pl) * | 2002-12-20 | 2006-02-06 | Biogen Idec Ma Inc. | Czynniki dla receptora limfotoksyny beta w połączeniu z czynnikami chemioterapeutycznymi |
EP1583503A4 (en) * | 2002-12-20 | 2006-08-09 | Biogen Idec Inc | POLYVALENT LYMPHOTOXIN BETA RECEPTOR AGONISTS AND THERAPEUTIC USE THEREOF |
JP5091476B2 (ja) | 2003-06-27 | 2012-12-05 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用 |
WO2005092927A1 (en) | 2004-03-23 | 2005-10-06 | Biogen Idec Ma Inc. | Receptor coupling agents and therapeutic uses thereof |
WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
EP1764371A1 (de) * | 2005-04-25 | 2007-03-21 | Xantos Biomedicine AG | Agonistische Antikörper, welche an den LT-Beta-Rezeptor binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie |
WO2008042436A2 (en) | 2006-10-03 | 2008-04-10 | Biogen Idec Ma Inc. | Biomarkers and assays for the treatment of cancer |
US8338376B2 (en) | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
US8067375B2 (en) | 2006-10-20 | 2011-11-29 | Biogen Idec Ma Inc. | Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor |
BRPI0913687A2 (pt) * | 2008-09-30 | 2015-10-13 | Genentech Inc | marcadores biológicos preditivos da resposta da artrite reumatóide aos antagonistas da linfotoxina |
IN2014CN04961A (zh) * | 2011-12-05 | 2015-09-18 | Igenica Biotherapeutics Inc | |
IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるltbrアゴニスト |
WO2023198848A1 (en) | 2022-04-13 | 2023-10-19 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6124599A (ja) * | 1984-07-11 | 1986-02-03 | Kyowa Hakko Kogyo Co Ltd | 新規ヒトインタ−フエロン−rポリペプチド誘導体 |
JPS61277628A (ja) * | 1985-06-04 | 1986-12-08 | Asahi Chem Ind Co Ltd | 癌治療用白血球刺激材 |
US4770995A (en) * | 1985-08-29 | 1988-09-13 | New York Blood Center, Inc | Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin |
AU8228891A (en) * | 1990-06-27 | 1992-01-23 | Biogen, Inc. | Surface complexed lymphotoxin |
EP0672143B1 (en) * | 1992-12-04 | 2008-06-04 | Biogen Idec MA Inc. | Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof |
-
1996
- 1996-01-26 EE EE9700255A patent/EE04453B1/xx not_active IP Right Cessation
- 1996-01-26 JP JP8523078A patent/JPH10513161A/ja not_active Withdrawn
- 1996-01-26 CN CNA2004100070585A patent/CN1589902A/zh active Pending
- 1996-01-26 KR KR1019970705213A patent/KR100470739B1/ko not_active IP Right Cessation
- 1996-01-26 DK DK96906260T patent/DK0809510T3/da active
- 1996-01-26 RO RO97-01398A patent/RO118634B1/ro unknown
- 1996-01-26 DE DE69632681T patent/DE69632681T2/de not_active Expired - Fee Related
- 1996-01-26 KR KR10-2004-7015796A patent/KR100475492B1/ko not_active IP Right Cessation
- 1996-01-26 PT PT96906260T patent/PT809510E/pt unknown
- 1996-01-26 SK SK986-97A patent/SK286497B6/sk not_active IP Right Cessation
- 1996-01-26 CZ CZ0236197A patent/CZ298711B6/cs not_active IP Right Cessation
- 1996-01-26 NZ NZ303405A patent/NZ303405A/en not_active IP Right Cessation
- 1996-01-26 PL PL96321758A patent/PL185364B1/pl unknown
- 1996-01-26 BR BR9606808A patent/BR9606808A/pt not_active Application Discontinuation
- 1996-01-26 WO PCT/US1996/001386 patent/WO1996022788A1/en active IP Right Grant
- 1996-01-26 EA EA199700144A patent/EA000096B1/ru not_active IP Right Cessation
- 1996-01-26 AT AT96906260T patent/ATE268604T1/de not_active IP Right Cessation
- 1996-01-26 HU HU9801746A patent/HUP9801746A3/hu unknown
- 1996-01-26 CN CNB961922710A patent/CN1146442C/zh not_active Expired - Fee Related
- 1996-01-26 ES ES96906260T patent/ES2220972T3/es not_active Expired - Lifetime
- 1996-01-26 EP EP20030022584 patent/EP1407781A1/en not_active Withdrawn
- 1996-01-26 CA CA002211443A patent/CA2211443A1/en not_active Abandoned
- 1996-01-26 AU AU49704/96A patent/AU725351B2/en not_active Ceased
- 1996-01-26 EP EP96906260A patent/EP0809510B1/en not_active Expired - Lifetime
- 1996-01-26 CN CNA2006101007130A patent/CN1900116A/zh active Pending
-
1997
- 1997-07-22 NO NO19973385A patent/NO322744B1/no not_active IP Right Cessation
- 1997-07-25 FI FI973118A patent/FI119359B/fi active IP Right Grant
- 1997-08-26 BG BG101855A patent/BG62599B1/bg unknown
-
1998
- 1998-06-02 HK HK98104772A patent/HK1006356A1/xx not_active IP Right Cessation
-
2007
- 2007-03-12 JP JP2007062695A patent/JP2007169296A/ja not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101073665B (zh) * | 2006-05-17 | 2014-11-26 | 上海复旦张江生物医药股份有限公司 | 淋巴毒素在制备增加化疗药物敏感性的药物中的应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1146442C (zh) | 作为抗肿瘤剂的淋巴毒素-α/β复合体和抗淋巴毒素-β受体抗体 | |
CN100467488C (zh) | Il-7融合蛋白 | |
KR101704865B1 (ko) | 항-ox40 항체 및 그의 용도 | |
JP7262597B2 (ja) | 二重特異性抗体及びその作製方法と使用 | |
AU688056B2 (en) | Surface complexed lymphotoxin | |
CN1399556A (zh) | April受体(bcma)及其用途 | |
CN1269832A (zh) | K-配体-新的免疫系统蛋白 | |
CN1192779A (zh) | 人b7.1和/或b7.2特异的猴源单克隆抗体灵长动物化形式,药用组合物 | |
CN1539970A (zh) | 嗜中性白细胞因子α | |
CN1196733A (zh) | 抗Fas配体抗体和利用抗Fas配体抗体的测定方法 | |
CN1891714A (zh) | 单纯疱疹病毒进入介体的配体和使用方法 | |
JPH08507201A (ja) | リンホトキシン‐β、リンホトキシン‐β複合体、それらの薬学的な調製物および治療への使用 | |
CN1404400A (zh) | Il-18抑制剂的应用 | |
CN1284134A (zh) | 利用毕赤氏酵母表达系统生产抗生血管蛋白质∶制管张素,内抑制素或静息蛋白的方法 | |
CN1237910A (zh) | 可溶性β-淋巴毒素受体和抗淋巴毒素受体的抗体以及抗淋巴毒素配体的抗体的用途 | |
CN1200733C (zh) | 阻断淋巴毒素β与其受体结合的物质在制备药物中的应用 | |
CN1489473A (zh) | 沉默型抗cd-28抗体及其应用 | |
US20230340054A1 (en) | Interleukin-2 muteins and uses thereof | |
CN1266714A (zh) | 人源化抗体 | |
CN1273191C (zh) | 用于改变b细胞介导病理的方法和组合物 | |
WO2023046097A1 (zh) | 抗tigit人源化抗体或其抗原结合片段及其应用 | |
CN1835769A (zh) | Kim-1拮抗剂及其在免疫系统调节中的应用 | |
CN1286976C (zh) | α/β-干扰素结合蛋白,制法及用途 | |
JP4447058B2 (ja) | ウシ泌乳関連向免疫性タンパク質(cd14)、コード遺伝子、およびb細胞活性化における適用 | |
US20060057112A1 (en) | Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: BIOGEN IDEC MASSACHUSETTS CORPORATION Free format text: FORMER NAME OR ADDRESS: BIOGEN IDEC MASSACHUSETTS, CO.,LTD. Owner name: BIOGEN IDEC MASSACHUSETTS, CO.,LTD. Free format text: FORMER NAME OR ADDRESS: BIOGEN, INC. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Massachusetts, USA Patentee after: Biogen Idec MA Inc. Address before: Massachusetts, USA Patentee before: Bayogen IDEC Massachusetts, Inc. Address after: Massachusetts, USA Patentee after: Bayogen IDEC Massachusetts, Inc. Address before: Massachusetts, USA Patentee before: Biogen, Inc. |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040421 Termination date: 20100228 |